Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel Free BCTXW Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

BriaCell Therapeutics (BCTXW) Financials

BriaCell Therapeutics logo
Compare
Annual Income Statements for BriaCell Therapeutics

Annual Income Statements for BriaCell Therapeutics

This table shows BriaCell Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 7/31/2020 7/31/2021 7/31/2022 7/31/2023 7/31/2024 7/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.09 -14 -27 -20 -4.79 -26
Consolidated Net Income / (Loss)		 -4.02 -14 -27 -20 -4.93 -27
Net Income / (Loss) Continuing Operations		 -4.11 -14 -27 -20 -4.93 -27
Total Pre-Tax Income 		-4.11 -14 -27 -20 -4.93 -27
Total Operating Income		 -4.02 -6.98 -15 -23 -33 -27
Total Gross Profit		 -0.09 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.09 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.94 6.98 15 23 33 27
Selling, General & Admin Expense		 1.51 4.96 7.27 7.94 6.15 5.93
Research & Development Expense		 2.43 2.02 8.02 15 27 21
Total Other Income / (Expense), net		 -0.09 -6.84 -12 2.97 28 0.65
Interest & Investment Income		 - - - 0.00 -0.11 -0.22
Other Income / (Expense), net		 -0.06 -6.84 -12 2.97 29 0.87
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - 0.00 -0.14 -0.24
Basic Earnings per Share		 ($5.64) ($3.06) ($1.73) ($1.30) ($43.68) ($62.19)
Weighted Average Basic Shares Outstanding		 713.89K 4.52M 15.49M 15.62M 109.70K 423.11K
Diluted Earnings per Share		 ($5.64) - ($1.73) ($1.30) ($43.68) ($62.19)
Weighted Average Diluted Shares Outstanding		 713.89K 4.52M 15.49M 15.62M 109.70K 423.11K
Weighted Average Basic & Diluted Shares Outstanding		 713.89K 4.52M 15.52M 15.98M 36.18M 1.88M

Quarterly Income Statements for BriaCell Therapeutics

This table shows BriaCell Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q3 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 4/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.42 6.00 -11 1.72 -1.21 -5.80 -6.29 -6.13 -8.09 -8.20 -7.16
Consolidated Net Income / (Loss)		 -2.42 5.96 -11 1.69 -1.25 -5.83 -6.34 -6.22 -8.16 -8.28 -7.24
Net Income / (Loss) Continuing Operations		 -2.42 5.96 -11 1.69 -1.25 -5.83 -6.34 -6.22 -8.15 -8.28 -7.24
Total Pre-Tax Income 		-2.42 5.96 -11 1.69 -1.25 -5.83 -6.34 -6.22 -8.22 -8.28 -7.17
Total Operating Income		 -7.71 -8.50 -9.83 -9.23 -5.77 -5.15 -7.17 -6.33 -8.55 -8.32 -7.62
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 7.71 8.50 9.83 9.23 5.77 5.15 7.17 6.33 8.55 8.32 7.62
Selling, General & Admin Expense		 2.54 1.65 1.57 1.57 1.36 1.49 1.48 1.52 1.44 1.64 1.65
Research & Development Expense		 5.17 6.86 8.26 7.66 4.41 3.67 5.68 4.81 7.11 6.68 5.97
Total Other Income / (Expense), net		 5.29 14 -1.50 11 4.52 -0.68 0.83 0.10 0.33 0.04 0.45
Other Income / (Expense), net		 5.29 14 -1.49 11 4.57 -0.60 0.87 0.17 0.45 0.09 0.45
Other Gains / (Losses), net		 - - - - - - - - - - -0.06
Net Income / (Loss) Attributable to Noncontrolling Interest		 - -0.04 -0.04 -0.02 -0.03 -0.03 -0.05 -0.10 -0.07 -0.08 -0.07
Basic Earnings per Share		 ($0.14) $0.38 ($10.64) $1.61 ($11.07) ($32.67) ($2.33) ($16.42) ($19.12) ($4.35) ($0.99)
Weighted Average Basic Shares Outstanding		 15.62M 15.98M 1.07M 1.07M 109.70K 177.61K 2.70M 373.07K 423.11K 1.88M 7.25M
Diluted Earnings per Share		 ($0.14) ($0.50) ($10.64) $1.61 ($11.07) ($32.67) ($2.33) ($16.42) ($19.12) ($4.35) ($0.99)
Weighted Average Diluted Shares Outstanding		 15.62M 16.67M 1.07M 1.07M 109.70K 177.61K 2.70M 373.07K 423.11K 1.88M 7.25M
Weighted Average Basic & Diluted Shares Outstanding		 15.98M 15.98M 15.98M 18.28M 36.18M 44.20M 3.71M 6.78M 1.88M 1.88M 8.70M

Annual Cash Flow Statements for BriaCell Therapeutics

This table details how cash moves in and out of BriaCell Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 7/31/2020 7/31/2021 7/31/2022 7/31/2023 7/31/2024 7/31/2025
Net Change in Cash & Equivalents		 -0.09 57 -16 -20 -20 9.63
Net Cash From Operating Activities		 -1.31 -7.75 -12 -24 -24 -28
Net Cash From Continuing Operating Activities		 -1.31 -7.75 -12 -24 -24 -28
Net Income / (Loss) Continuing Operations		 -4.02 -14 -27 -20 -4.93 -27
Consolidated Net Income / (Loss)		 -4.02 -14 -27 -20 -4.93 -27
Depreciation Expense		 0.02 0.02 - 0.00 0.07 0.09
Amortization Expense		 - - 0.02 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 -0.29 8.33 15 0.07 -26 0.19
Changes in Operating Assets and Liabilities, net		 2.91 -2.28 -0.39 -3.53 7.05 -1.91
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 -0.68 -7.65
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 -0.68 -7.65
Purchase of Property, Plant & Equipment		 - - - 0.00 -0.46 0.00
Purchase of Investments		 - - - 0.00 -0.23 -7.65
Net Cash From Financing Activities		 1.17 65 -3.74 3.95 4.42 45
Net Cash From Continuing Financing Activities		 1.17 65 -3.74 3.95 4.42 45
Issuance of Common Equity		 - 52 0.00 4.00 4.42 45
Other Financing Activities, net		 - 14 6.49 0.00 0.00 0.82

Quarterly Cash Flow Statements for BriaCell Therapeutics

This table details how cash moves in and out of BriaCell Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025
Net Change in Cash & Equivalents		 -6.92 -7.61 -7.40 -5.31 -0.07 4.93 -0.78 7.45 -1.97 -7.78
Net Cash From Operating Activities		 -11 -7.61 -7.40 -5.08 -4.04 -6.96 -5.92 -7.16 -8.13 -7.70
Net Cash From Continuing Operating Activities		 -11 -7.61 -7.40 -5.08 -4.04 -6.96 -5.92 -7.16 -8.13 -7.70
Net Income / (Loss) Continuing Operations		 -2.42 5.96 -11 1.69 -1.25 -5.83 -6.34 -6.22 -8.16 -8.28
Consolidated Net Income / (Loss)		 -2.42 5.96 -11 1.69 -1.25 -5.83 -6.34 -6.22 -8.16 -8.28
Depreciation Expense		 -0.01 0.00 0.01 0.00 0.06 0.02 0.03 0.02 0.01 0.02
Amortization Expense		 - 0.00 - - - 0.00 - - - 0.00
Non-Cash Adjustments To Reconcile Net Income		 -4.56 -14 2.09 -11 -4.15 0.96 -0.48 0.11 -0.40 1.21
Changes in Operating Assets and Liabilities, net		 -3.95 0.18 1.84 3.74 1.29 -2.11 0.87 -1.08 0.41 -0.66
Net Cash From Investing Activities		 - 0.00 - -0.23 -0.46 -0.08 -0.08 -0.11 -7.39 -0.08
Net Cash From Continuing Investing Activities		 - 0.00 - -0.23 -0.46 -0.08 -0.08 -0.11 -7.39 -0.08
Purchase of Investments		 - 0.00 - -0.23 - -0.08 -0.08 -0.11 -7.39 -0.08
Net Cash From Financing Activities		 4.00 0.00 - - 4.42 12 5.22 15 14 0.00
Net Cash From Continuing Financing Activities		 4.00 0.00 - - 4.42 12 5.22 15 14 0.00
Issuance of Common Equity		 - 0.00 - - 4.42 12 4.69 15 14 0.00
Other Financing Activities, net		 - 0.00 - - - 0.29 0.53 - - 0.00

Annual Balance Sheets for BriaCell Therapeutics

This table presents BriaCell Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 8/1/2019 7/31/2020 7/31/2021 7/31/2022 7/31/2023 7/31/2024 7/31/2025
Total Assets		 0.44 0.52 58 43 27 5.87 22
Total Current Assets		 0.17 0.24 58 42 27 3.65 20
Cash & Equivalents		 0.16 0.02 57 41 21 0.86 10
Short-Term Investments		 - - - - - 0.00 7.37
Prepaid Expenses		 0.01 0.22 0.52 1.28 5.70 2.79 2.06
Plant, Property, & Equipment, net		 15 18 0.00 0.00 0.00 0.39 0.30
Total Noncurrent Assets		 0.28 0.28 0.25 0.23 0.22 1.83 1.43
Goodwill		 - - - - - - 0.18
Other Noncurrent Operating Assets		 0.28 0.26 - - 0.00 1.63 1.24
Total Liabilities & Shareholders' Equity		 15 19 58 43 27 5.87 22
Total Liabilities		 1.13 4.12 30 32 31 8.56 4.32
Total Current Liabilities		 1.13 3.96 0.56 0.94 1.80 7.46 3.98
Accounts Payable		 0.81 3.71 0.56 0.94 1.80 7.46 3.98
Total Noncurrent Liabilities		 0.00 0.16 30 31 29 1.10 0.34
Other Noncurrent Operating Liabilities		 0.00 0.00 30 31 29 1.10 0.34
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 15 28 10 -3.78 -2.68 17
Total Preferred & Common Equity		 14 15 28 10 -3.78 -2.38 18
Total Common Equity		 14 15 28 10 -3.78 -2.38 18
Common Stock		 11 12 57 66 70 72 102
Retained Earnings		 - - -29 -60 -81 -85 -112
Accumulated Other Comprehensive Income / (Loss)		 -0.10 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14
Other Equity Adjustments		 3.05 2.45 - 5.23 7.42 11 28
Noncontrolling Interest		 - - - - 0.00 -0.30 -0.55

Quarterly Balance Sheets for BriaCell Therapeutics

This table presents BriaCell Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q3 2026
Period end date 10/31/2023 1/31/2024 4/30/2024 10/31/2024 1/31/2025 4/30/2025 10/31/2025 4/30/2026
Total Assets		 19 12 6.20 10 9.36 17 13 27
Total Current Assets		 18 12 5.53 8.22 7.16 15 11 25
Cash & Equivalents		 14 6.24 0.94 5.79 5.01 12 2.71 6.88
Short-Term Investments		 - - - - - - 7.46 16
Prepaid Expenses		 4.74 5.47 4.58 2.43 2.15 2.32 1.17 2.59
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.37 0.34 0.32 0.27 0.35
Total Noncurrent Assets		 0.21 0.49 0.67 1.83 1.86 1.90 1.45 1.33
Goodwill		 - - - - - - - 0.17
Other Noncurrent Operating Assets		 - 0.28 0.47 1.63 1.67 1.71 1.27 1.16
Total Liabilities & Shareholders' Equity		 19 12 6.20 10 9.36 17 13 27
Total Liabilities		 16 21 12 6.70 6.14 5.06 3.72 3.66
Total Current Liabilities		 1.05 3.92 6.76 4.99 5.23 4.33 3.32 3.59
Accounts Payable		 1.05 3.92 6.76 4.99 5.23 4.33 3.32 3.59
Total Noncurrent Liabilities		 15 17 5.68 1.71 0.91 0.73 0.41 0.07
Other Noncurrent Operating Liabilities		 15 17 5.68 1.71 0.91 0.73 0.41 0.07
Commitments & Contingencies		 - - - - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 2.52 -8.32 -6.23 3.71 3.23 12 9.35 23
Total Preferred & Common Equity		 2.72 -8.07 -5.97 4.04 3.60 12 9.98 24
Total Common Equity		 2.72 -8.07 -5.97 4.04 3.60 12 9.98 24
Common Stock		 78 70 70 82 85 94 102 117
Retained Earnings		 -75 -86 -84 -91 -98 -104 -120 -134
Accumulated Other Comprehensive Income / (Loss)		 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14
Other Equity Adjustments		 - 8.42 8.81 13 16 22 28 41
Noncontrolling Interest		 -0.21 -0.24 -0.27 -0.33 -0.38 -0.47 -0.63 -0.65

Annual Metrics And Ratios for BriaCell Therapeutics

This table displays calculated financial ratios and metrics derived from BriaCell Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 7/31/2020 7/31/2021 7/31/2022 7/31/2023 7/31/2024 7/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 15,981,726.00 18,284,661.00 6,776,092.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 106,545.00 121,898.00 677,609.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 -190.55 -39.31 -38.83
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -239.52% -94.36% 24.37% 76.63% -453.14%
EBIT Growth		 0.00% -238.62% -94.26% 24.35% 76.23% -445.74%
NOPAT Growth		 0.00% -73.34% -119.16% -52.22% -43.22% 18.38%
Net Income Growth		 0.00% -243.30% -94.26% 24.35% 75.71% -438.50%
EPS Growth		 0.00% 0.00% 0.00% 24.86% 75.71% -438.50%
Operating Cash Flow Growth		 0.00% -491.68% -61.08% -90.20% -1.61% -16.76%
Free Cash Flow Firm Growth		 0.00% 0.00% -124.12% -129.85% -103.92% 50.78%
Invested Capital Growth		 0.00% -297.71% -3.86% 18.51% 85.83% 84.99%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 2.47% 21.58% -35.97%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 2.40% 20.20% -35.56%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -11.88% 5.49% -11.41%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -475.66% 19.17% -35.21%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 19.17% -35.21%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% -47.01% 22.20% -17.02%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 13.12% 7.09%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 26.52% 50.52% -2.53%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 97.93% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.72% 100.00% 100.00% 100.00% 102.21% 100.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -28.11% -65.41% -141.26% -619.75% 152.63% -362.56%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -28.11% -65.41% -141.26% -619.75% 145.48% -383.58%
Return on Equity Simple (ROE_SIMPLE)		 -27.62% -49.93% -259.84% 537.50% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.82 -4.88 -11 -16 -23 -19
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 314.02% -31.42% -32.84% -12.88% 166.41% -80.23%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 868.96% -109.86%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.08 -14 -27 -20 -4.83 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.06 -14 -27 -20 -4.74 -26
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.28
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.29
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.03 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.03 -1.35 -2.59 -9.51 3.42 -1.28
Leverage Ratio		 0.03 1.39 2.65 10.64 -5.11 1.88
Compound Leverage Factor		 0.03 1.39 2.65 10.64 -5.23 1.89
Debt to Total Capital		 2.71% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 11.27% -3.15%
Common Equity to Total Capital		 97.29% 100.00% 100.00% 100.00% 88.73% 103.15%
Debt to EBITDA		 -0.10 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.09 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.04 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.14 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -0.14 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.06 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -3.05 -22.90 -9.65
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 4.68% -5.80%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.06 103.81 45.00 14.96 0.49 5.01
Quick Ratio		 0.01 102.88 43.64 11.80 0.12 4.49
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 40 -9.56 -22 -45 -22
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -5,281.54% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -44.43 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -44.43 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.04 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 9,703.95 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 15 -30 -31 -25 -3.55 -0.53
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -45 -1.14 5.68 21 3.01
Enterprise Value (EV)		 0.00 0.00 0.00 106 13 -13
Market Capitalization		 0.00 0.00 0.00 127 14 5.05
Book Value per Share		 $20.41 $6.12 $0.67 ($0.24) ($0.13) $2.64
Tangible Book Value per Share		 $20.41 $6.07 $0.65 ($0.25) ($0.14) $2.61
Total Capital		 15 28 10 -3.78 -2.68 17
Total Debt		 0.41 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.16 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.38 -57 -41 -21 -0.86 -18
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.46 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.50 -0.03 0.36 3.90 -4.67 -1.92
Debt-free Net Working Capital (DFNWC)		 -3.48 57 41 25 -3.81 16
Net Working Capital (NWC)		 -3.72 57 41 25 -3.81 16
Net Nonoperating Expense (NNE)		 1.21 8.93 16 4.01 -18 7.51
Net Nonoperating Obligations (NNO)		 0.38 -57 -41 -21 -0.86 -18
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.02 0.02 0.08 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.09) ($1.73) ($1.30) ($43.50) ($62.19)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 4.52M 15.49M 15.62M 109.70K 423.11K
Adjusted Diluted Earnings per Share		 $0.00 ($0.09) $0.00 ($1.30) ($43.50) ($62.19)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 4.52M 15.52M 15.62M 109.70K 423.11K
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.09) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 4.52M 15.52M 15.98M 241.22K 1.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.82 -4.88 -11 -16 -23 -19
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -138.40 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -95.56 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -138.40 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -95.56 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -38.11% -0.23% 0.00% 0.00%

Quarterly Metrics And Ratios for BriaCell Therapeutics

This table displays calculated financial ratios and metrics derived from BriaCell Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q3 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 4/30/2026
DEI Shares Outstanding		 15,981,726.00 15,981,726.00 15,981,726.00 15,981,726.00 18,284,661.00 36,183,161.00 44,204,161.00 3,709,440.00 6,776,092.00 1,883,906.00 1,883,906.00
DEI Adjusted Shares Outstanding		 106,545.00 106,545.00 106,545.00 106,545.00 121,898.00 241,221.00 294,694.00 370,944.00 677,609.00 1,883,906.00 1,883,906.00
DEI Earnings Per Adjusted Shares Outstanding		 -22.70 56.33 -106.01 16.10 -9.96 -24.05 -21.35 -16.52 -11.94 -4.35 -3.80
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 53.57% 640.72% 4.80% 135.43% 53.07% -196.12% 44.60% -454.69% -609.71% -43.20% -16.69%
EBIT Growth		 53.79% 638.51% 4.77% 135.32% 50.49% -196.63% 44.37% -456.35% -576.78% -43.00% -16.40%
NOPAT Growth		 -3.06% -124.82% -119.10% -132.26% 25.15% 57.58% 27.06% 52.00% -48.31% -61.52% -20.42%
Net Income Growth		 -116.85% 638.51% 4.61% 134.57% 48.37% -197.83% 44.08% -467.85% -553.78% -42.01% -16.26%
EPS Growth		 0.00% -614.29% 4.61% 134.57% 48.37% -197.83% 78.10% -467.85% -553.78% 86.69% 93.97%
Operating Cash Flow Growth		 -228.32% -114.69% -87.29% 4.65% 63.04% 8.55% 20.01% -40.89% -101.51% -10.78% 0.00%
Free Cash Flow Firm Growth		 0.00% -204.95% -185.65% -220.06% -130.35% 48.32% 34.34% 69.33% 64.72% 44.07% 41.71%
Invested Capital Growth		 18.51% 58.96% 58.13% 78.95% 85.83% 81.32% 87.73% 92.76% 84.99% 60.29% 216.46%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 50.32% 345.37% -289.64% 115.33% -165.80% -402.55% -9.09% 1.88% -31.91% -1.40% 0.00%
EBIT Q/Q Growth		 50.59% 346.37% -289.89% 115.28% -169.26% -380.78% -9.11% 2.11% -31.53% -1.59% 0.00%
NOPAT Q/Q Growth		 -35.74% -57.64% 19.08% -34.14% 56.25% 10.66% -39.14% 11.73% -35.18% 2.70% 0.00%
Net Income Q/Q Growth		 50.59% 346.37% -290.20% 114.93% -173.79% -366.81% -8.72% 1.78% -31.15% -1.40% 0.00%
EPS Q/Q Growth		 56.25% -257.14% -290.20% 114.93% -173.79% -366.81% -959.09% 1.78% -31.15% 77.25% 0.00%
Operating Cash Flow Q/Q Growth		 -104.79% 30.35% 2.68% 31.31% 20.62% -72.34% 14.88% -20.99% -13.54% 5.26% 0.00%
Free Cash Flow Firm Q/Q Growth		 -136.82% -121.07% -10.65% -33.30% 29.36% 50.40% -40.58% 37.73% 18.74% 21.36% 0.00%
Invested Capital Q/Q Growth		 26.52% 55.53% -30.84% 50.77% 50.52% 41.38% 14.07% 70.95% -2.53% -55.11% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.27% 100.00% 100.90%
Interest Burden Percent		 100.00% 100.00% 100.16% 97.86% 104.27% 101.24% 100.68% 101.02% 101.47% 100.54% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -619.75% -206.01% 264.41% 100.64% 152.63% -536.81% 460.60% -688.17% -362.56% -444.07% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -619.75% -209.30% 257.68% 98.42% 145.48% -582.89% 404.46% -777.62% -383.58% -476.61% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -486.40% 157.18% 102.29% 0.00% 0.00% -325.39% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.39 -8.50 -6.88 -9.23 -4.04 -3.61 -5.02 -4.43 -5.99 -5.83 -5.33
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 9.55% 56.60% -22.41% 75.05% 25.22% -22.87% -23.44% -26.80% -23.24% -30.71% -10.79%
Return On Investment Capital (ROIC_SIMPLE)		 - -337.92% 82.73% 148.08% 150.38% -97.14% -155.52% -37.10% -34.54% -62.31% -22.79%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.42 5.96 -11 1.73 -1.20 -5.76 -6.30 -6.16 -8.11 -8.23 -7.17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.43 5.96 -11 1.73 -1.14 -5.73 -6.26 -6.15 -8.09 -8.21 -7.17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 24.96 0.00 0.00 0.00 7.28 4.11 1.33 0.28 2.08 0.33
Price to Tangible Book Value (P/TBV)		 0.00 27.06 0.00 0.00 0.00 7.65 4.34 1.35 0.29 2.12 0.33
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -9.51 -3.98 4.14 2.40 3.42 -3.12 2.21 -2.35 -1.28 -1.22 -1.00
Leverage Ratio		 10.64 4.44 -4.83 -2.96 -5.11 4.66 -4.24 4.07 1.88 1.80 1.25
Compound Leverage Factor		 10.64 4.44 -4.84 -2.90 -5.33 4.72 -4.27 4.11 1.91 1.81 1.25
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -8.15% 2.94% 4.30% 11.27% -8.88% -11.65% -3.97% -3.15% -6.71% -2.77%
Common Equity to Total Capital		 100.00% 108.15% 97.06% 95.70% 88.73% 108.88% 111.65% 103.97% 103.15% 106.71% 102.77%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.88 -0.91 -10.20 -16.65 -20.86 -11.08 -15.11 -7.03 -6.88 -10.85 0.00
Noncontrolling Interest Sharing Ratio		 0.00% -1.60% 2.55% 2.21% 4.68% -8.58% 12.19% -13.00% -5.80% -7.33% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.96 17.59 2.99 0.82 0.49 1.65 1.37 3.41 5.01 3.42 7.07
Quick Ratio		 11.80 13.06 1.60 0.14 0.12 1.16 0.96 2.88 4.49 3.07 6.35
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -24 -27 -36 -26 -13 -18 -11 -9.00 -7.08 -6.46
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -25 -11 -15 -7.17 -3.55 -2.08 -1.79 -0.52 -0.53 -0.83 0.60
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 5.68 16 20 27 21 9.05 13 6.65 3.01 1.25 1.12
Enterprise Value (EV)		 106 54 59 33 13 23 9.40 3.61 -13 9.92 -16
Market Capitalization		 127 68 66 35 14 29 15 17 5.05 21 7.87
Book Value per Share		 ($0.24) $0.17 ($0.51) ($0.37) ($0.13) $0.11 $0.08 $3.35 $2.64 $5.30 $3.32
Tangible Book Value per Share		 ($0.25) $0.16 ($0.52) ($0.39) ($0.14) $0.11 $0.08 $3.30 $2.61 $5.20 $3.29
Total Capital		 -3.78 2.52 -8.32 -6.23 -2.68 3.71 3.23 12 17 9.35 23
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -21 -14 -6.24 -0.94 -0.86 -5.79 -5.01 -12 -18 -10 -23
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.90 3.72 1.57 -2.16 -4.67 -2.56 -3.08 -2.01 -1.92 -2.15 -1.00
Debt-free Net Working Capital (DFNWC)		 25 17 7.82 -1.23 -3.81 3.23 1.93 10 16 8.03 22
Net Working Capital (NWC)		 25 17 7.82 -1.23 -3.81 3.23 1.93 10 16 8.03 22
Net Nonoperating Expense (NNE)		 -2.98 -14 4.45 -11 -2.79 2.22 1.32 1.80 2.18 2.45 1.90
Net Nonoperating Obligations (NNO)		 -21 -14 -6.24 -0.94 -0.86 -5.79 -5.01 -12 -18 -10 -23
Total Depreciation and Amortization (D&A)		 -0.01 0.00 0.01 0.00 0.06 0.03 0.03 0.02 0.01 0.03 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.14) $0.38 ($10.65) $1.65 ($1,660.50) ($33.00) ($2.33) ($16.40) ($191.20) ($4.35) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 15.62M 15.98M 1.07M 1.07M 731.00 177.61K 2.70M 373.55K 42.31K 1.88M 7.25M
Adjusted Diluted Earnings per Share		 ($0.14) ($0.50) ($10.65) $1.65 ($1,660.50) ($33.00) ($2.33) ($16.40) ($191.20) ($4.35) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 15.62M 16.67M 1.07M 1.07M 731.00 177.61K 2.70M 373.55K 42.31K 1.88M 7.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1,660.50) $0.00 $0.00 $0.00 ($191.20) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 15.98M 15.98M 1.07M 1.22M 241.22K 294.69K 3.71M 677.61K 188.39K 1.88M 8.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.39 -5.95 -6.88 -6.46 -4.04 -3.61 -5.02 -4.43 -5.99 -5.83 -5.33
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Briacell Therapeutics (NASDAQ: BCTX) remains a pre-revenue biotech story with a very large cash position relative to its market cap, but the latest quarterly results also show persistent operating losses and ongoing dependence on equity financing.

  • Cash and short-term investments rose sharply to $22.8 million in Q3 2026, up from $10.2 million in Q1 2026, giving the company a larger near-term liquidity cushion.
  • Total equity improved to $23.4 million in Q3 2026, up from $9.4 million in Q1 2026, helped by financing and balance sheet growth.
  • The company continues to carry relatively low total liabilities of $3.7 million, which helps limit balance sheet risk compared with many early-stage biotech peers.
  • Financing activity in Q4 2025 and Q1 2025 materially boosted cash, showing the company can still access capital when needed.
  • Operating expenses remained focused on development, with R&D spending still the largest expense category, consistent with a clinical-stage biotech model.
  • The company reported no revenue in every quarter provided, so the investment case still depends on clinical progress rather than sales growth.
  • Q3 2026 net loss attributable to common shareholders was $7.2 million, or -$0.99 per share, showing the business is still burning cash at a meaningful rate.
  • Operating cash flow was negative $7.7 million in Q3 2026, which means the core business is not yet self-funding.
  • Year-over-year, cash and equivalents fell from $12.5 million in Q3 2025 to $6.9 million in Q3 2026, despite the later rebound from short-term investments.
  • Share count has increased significantly over time, indicating dilution remains a major risk for existing shareholders.

Looking across the last four years, the most important trend is that BCTX is still a cash-consuming biotech with no revenue and recurring losses. That said, the balance sheet is currently supported by a sizable cash-and-investment reserve and limited debt, which gives management room to continue development.

For retail investors, the key question is whether the company can translate its clinical pipeline into meaningful value before dilution erodes too much of the upside. In the near term, liquidity looks manageable, but the operating model still points to continued cash burn and future financing needs.

07/20/26 10:43 PM ETAI Generated. May Contain Errors.

BriaCell Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BriaCell Therapeutics' fiscal year ends in July. Their fiscal year 2025 ended on July 31, 2025.

BriaCell Therapeutics' net income appears to be on an upward trend, with a most recent value of -$26.56 million in 2025, rising from -$4.02 million in 2020. The previous period was -$4.93 million in 2024.

BriaCell Therapeutics' total operating income in 2025 was -$27.20 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $27.20 million

Over the last 5 years, BriaCell Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

BriaCell Therapeutics' total liabilities were at $4.32 million at the end of 2025, a 49.6% decrease from 2024, and a 280.8% increase since 2019.

In the past 6 years, BriaCell Therapeutics' cash and equivalents has ranged from $21.25 thousand in 2020 to $57.27 million in 2021, and is currently $10.49 million as of their latest financial filing in 2025.

Over the last 5 years, BriaCell Therapeutics' book value per share changed from 20.41 in 2020 to 2.64 in 2025, a change of -87.1%.


Related Companies

Financial statements for NASDAQ:BCTXW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
NVIDIA offered $40B. The answer was no.
Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...
Behind the Markets | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump is positioned. Elon lights the fuse.
Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...
Crypto 101 Media | Sponsoredtc pixel